List
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: Lymphoma, Follicular. 16 results shown below.
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Complete title: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Principal Investigator: Mazyar Shadman
Study Number: 9738
Phase: I/II
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
Complete title: A Phase I Study Evaluating Copanlisib in Combination with R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular Lymphoma
Principal Investigator: Ryan Lynch
Study Number: RG1005097
Phase: I
Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Complete title: Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients with Hematologic Malignancies
Principal Investigator: Andrew Cowan
Study Number: RG1005491
Phase: II
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Complete title: Hematopoietic Stem Cell Transplantation from Haploidentical Donors in Patients with Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
Principal Investigator: Filippo Milano
Study Number: RG1005742
Phase: II
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Complete title: Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Principal Investigator: Chaitra Ujjani
Study Number: 10076
Phase: I/II
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Principal Investigator: Rachel Salit
Study Number: 2372.00
Phase: II
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Complete title: A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients with CD30+ Malignancies Refractory to Every 3 Week Brentuximab Vedotin
Principal Investigator: Ajay Gopal, MD
Study Number: 7808
Phase: II
Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Complete title: Phase II Study of Anti-CD20 Antibody Therapy Plus Pembrolizumab (MK-3475) in Subjects with Relapsed Follicular and Diffuse Large B-Cell Lymphoma
Principal Investigator: Stephen Smith
Study Number: 9469
Phase: II
Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Complete title: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Principal Investigator: Mazyar Shadman
Study Number: S1608
Phase: II
Safety Study of SEA-CD40 in Cancer Patients
Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies
Principal Investigator: Andrew Coveler, MD
Study Number: 20150420
Phase: I
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)
Complete title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Principal Investigator: Ryan Lynch
Study Number: 20161033
Phase: II/III
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Complete title: A Phase 1 Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)
Principal Investigator: Michael Schweizer
Study Number: 20181583
Phase: I
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)
Complete title: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory(R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Principal Investigator: David Maloney, MD, PhD
Study Number: 9734
Phase: I
A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Complete title: An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses Of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Principal Investigator: Mazyar Shadman
Study Number: 9837
Phase: I
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)
Complete title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (INHL)
Principal Investigator: David Maloney, MD, PhD
Study Number: 9876
Phase: II
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Complete title: A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of
Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin
Lymphomas
Principal Investigator: Ajay Gopal, MD
Study Number: RG1005774
Phase: I